Drugs / anti-EX02 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06196658 | Jan 2024 → Dec 2026 expected | biliary tract cancer, malignant pancreatic neoplasm | Zhang Xiaofeng,MD | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-EX02 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06196658 ↗ |
| Known as | EX02 CAR-T | “Early Phase I Study of Autologous T Cells Engineered to Express Anti-EX02 Chimeric Antigen Receptor (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer” NCT06196658 ↗ |
| Modality | Cell therapy | “EX02 CAR T cell therapy” NCT06196658 ↗ |
| Route | Other | “Intraperitoneal infusion or intra-tumoral injection of anti-EX02 CAR T cells” NCT06196658 ↗ |